What is Alan Laboratories?
Alan Laboratories operates as a high-authority specialty contract research organization (CRO) with a core focus on advanced solid dose formulation technologies. The company distinguishes itself through expertise in sustained-release, extended-release, and delayed-release mechanisms, providing essential analytical and pre-formulation services. Since its inception, the firm has leveraged its unique technical infrastructure to assist pharmaceutical partners in navigating the complexities of hard-to-formulate products. Furthermore, Alan Laboratories actively utilizes its internal technology stack to advance 505(b)(2) NDA candidates, effectively bridging the gap between existing drug assets and improved therapeutic delivery systems.
How much funding has Alan Laboratories raised?
Alan Laboratories has raised a total of $111K across 1 funding round:
Debt
$111K
Debt (2021): $111K with participation from PPP
Key Investors in Alan Laboratories
PPP
Public-Private Partnership
What's next for Alan Laboratories?
With the recent strategic investment, Alan Laboratories is poised to transition into a more aggressive growth phase, likely focusing on the commercialization of its 505(b)(2) pipeline. The company's trajectory suggests a shift toward scaling its proprietary formulation platforms to meet the rising demand for controlled-release therapeutics. By deepening its long-term collaborations with major pharmaceutical entities, the firm is expected to enhance its operational capacity and solidify its reputation as a premier partner for complex drug development. Future milestones will likely involve expanding its laboratory infrastructure and increasing its portfolio of proprietary drug candidates, ensuring sustained competitive advantage in the evolving pharmaceutical landscape.
See full Alan Laboratories company page
